Physician profile
Susan E Heverling
NPI 1750358701
$6,277.65
in general payments reported to CMS, 2019-2025
34 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $945 · 2021: $866 · 2022: $992 · 2023: $952 · 2024: $811 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,660.73 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $522.91 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $487.20 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $446.38 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $337.60 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $322.47 | 2021-2025 | Evenity, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $277.67 | 2019-2025 | |
| Novo Nordisk INC | $274.92 | 2019-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $261.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $247.90 | 2019-2022 | |
| Pfizer INC. | $244.66 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $172.50 | 2019-2022 | |
| Eisai INC. | $118.04 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.00 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $92.68 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $81.15 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $61.11 | 2022 | |
| Nestle Healthcare Nutrition INC. | $55.73 | 2022 | |
| Idorsia Pharmaceuticals US INC | $54.60 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $53.16 | 2021 | |
| Exact Sciences Corporation | $50.94 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.72 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $45.32 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $42.80 | 2020-2021 | |
| Medtronic, INC. | $39.63 | 2022-2025 | Minimed 780g |
| Baxter Healthcare | $24.14 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2019 | |
| Radius Health, INC. | $19.67 | 2025 | Tymlos |
| Janssen Biotech, INC. | $19.00 | 2021 | |
| Daiichi Sankyo INC. | $18.93 | 2024 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $17.17 | 2022 | |
| Mylan Specialty L.P. | $16.25 | 2024 | Yupelri |
| Alfasigma USA, INC. | $13.66 | 2020 | |
| Esperion Therapeutics, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Heverling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.